Randomized, double-blind comparison of acute beta1-blockade with 50 mg metoprolol tartrate vs 25 mg carvedilol in normal subjects.

Differential efficacy of immediate-release metoprolol tartrate and carvedilol in the treatment of congestive heart failure remains a subject of ongoing debate. The degree of beta1-blockade can be assessed by percentage reduction of exercise heart rate. Twelve healthy subjects underwent symptom-limited cardiopulmonary exercise testing repeated weekly and 2 hours after randomized, double-blind administration of 50 mg metoprolol tartrate vs 25 mg carvedilol. Baseline heart rate, heart rate at 40% and 70% peak O2 consumption, and maximal exercise were significantly blunted more by metoprolol tartrate than by carvedilol (P<.05 for all). Peak O2 consumption was significantly reduced by metoprolol tartrate (P<.03) but not by carvedilol (P=.054). The change in O2 consumption was significantly correlated with the degree of beta1-blockade (r =0.45; P<.05). In healthy subjects, a higher degree of beta1-blockade is achieved with 50 mg metoprolol tartrate compared with 25 mg carvedilol.

[1]  C. Lavie,et al.  Peak exercise oxygen pulse and prognosis in chronic heart failure. , 2004, The American journal of cardiology.

[2]  P. Poole‐Wilson,et al.  Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial , 2003, The Lancet.

[3]  B. Fagerberg,et al.  Dose of metoprolol CR/XL and clinical outcomes in patients with heart failure: analysis of the experience in metoprolol CR/XL randomized intervention trial in chronic heart failure (MERIT-HF). , 2002, Journal of the American College of Cardiology.

[4]  F. Fruhwald,et al.  Differing beta‐blocking effects of carvedilol and metoprolol , 2001, European journal of heart failure.

[5]  D. DeMets,et al.  Effect of carvedilol on survival in severe chronic heart failure. , 2001, The New England journal of medicine.

[6]  M. Domanski,et al.  A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. , 2001, The New England journal of medicine.

[7]  D. Jorkasky,et al.  Steady‐State Pharmacokinetics of Carvedilol and Its Enantiomers in Patients with Congestive Heart Failure , 2000, Journal of clinical pharmacology.

[8]  H. Whittle,et al.  Effect of subclinical infection on maintaining immunity against measles in vaccinated children in West Africa , 1999, The Lancet.

[9]  CIBIS-II Investigators and Committees The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial , 1999, The Lancet.

[10]  K. Adams,et al.  Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. MOCHA Investigators. , 1996, Circulation.

[11]  J. Cohn,et al.  The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. , 1996, The New England journal of medicine.

[12]  K. Breithaupt-Grögler,et al.  Reproducibility and consistency of the responses to supine bicycle ergometry; evaluation in conjunction with beta 1-adrenoceptor occupancies. , 1994, British journal of clinical pharmacology.

[13]  Hung‐Yuan Cheng,et al.  Carvedilol, a new vasodilator and beta adrenoceptor antagonist, is an antioxidant and free radical scavenger. , 1992, The Journal of pharmacology and experimental therapeutics.

[14]  J. Wilmore,et al.  Effects of beta-blockade on exercise capacity of trained and untrained men: a hemodynamic comparison. , 1986, Journal of applied physiology.

[15]  J. Wilmore,et al.  Effects of cardioselective and nonselective beta-adrenergic blockade on the performance of highly trained runners. , 1985, The American journal of cardiology.

[16]  W. Kraus,et al.  Effects of beta 1-selective and nonselective beta-adrenoceptor blockade during exercise conditioning in healthy adults. , 1984, The American journal of cardiology.

[17]  B. Whipp,et al.  Effects of beta-adrenergic blockade on ventilation and gas exchange during exercise in humans. , 1983, Journal of applied physiology: respiratory, environmental and exercise physiology.

[18]  D. Hosmer,et al.  Maximal oxygen intake and nomographic assessment of functional aerobic impairment in cardiovascular disease. , 1973, American heart journal.

[19]  P. Lundborg,et al.  Pharmacokinetics and pharmacodynamics of controlled-release metoprolol: A comparison with atenolol , 2004, European Journal of Clinical Pharmacology.

[20]  P. Rønnevik,et al.  Functional capacity in healthy volunteers before and following β-blockade with controlled-release metoprolol , 2004, European Journal of Clinical Pharmacology.